Trade Mark Journal No.2018/016 20 April 2018

UK00003301283 3 April 2018 (5)

AMLYCAS

International priority date claimed: 13 October 2017 () (017326174)
Class 5
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes.

Prothena Therapeutics Limited

Representative: HGF Limited